{
    "$schema": "https://github.com/Open-Systems-Pharmacology/QualificationPlan/releases/download/v1.0/OSP_Qualification_Plan_Schema.json",
    "Projects": [
        {
            "Id": "Atazanavir",
            "Path": "C:/Users/gemuh.AD-BAYER-CNB/Desktop/Markdown/Atazanavir/Input/Atazanavir.json",
            "BuildingBlocks": []
        }
    ],
    "Intro": [
        {
            "Path": "Content/titlepage.md"
        }
    ],
    "Plots": {
        "PlotSettings": {
            "ChartWidth": 500,
            "ChartHeight": 400,
            "Fonts": {
                "AxisSize": 11,
                "LegendSize": 9,
                "OriginSize": 9,
                "FontFamilyName": "Arial",
                "WatermarkSize": 40
            }
        },
        "AxesSettings": {
            "ComparisonTimeProfile": [
                {
                    "Unit": "h",
                    "Dimension": "Time",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Unit": "µg/l",
                    "Dimension": "Concentration (mass)",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "DDIRatioPlotsPredictedVsObserved": [
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "DDIRatioPlotsResidualsVsObserved": [
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Linear"
                }
            ],
            "GOFMergedPlotsPredictedVsObserved": [
                {
                    "Unit": "µg/l",
                    "Dimension": "Concentration (mass)",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Unit": "µg/l",
                    "Dimension": "Concentration (mass)",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "GOFMergedPlotsResidualsOverTime": [
                {
                    "Unit": "h",
                    "Dimension": "Time",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Linear"
                }
            ],
            "PKRatioPlots": [
                {
                    "Unit": "year(s)",
                    "Dimension": "Age",
                    "Type": "X",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Unit": "",
                    "Dimension": "Dimensionless",
                    "Type": "Y",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ]
        },
        "GOFMergedPlots": [
            {
                "Title": "Goodness-of-fit visual diagnostic plots for atazanavir PBPK model performance: observed versus simulated plasma concentrations",
                "SectionId": 41,
                "PlotType": "predictedVsObserved",
                "Groups": [
                    {
                        "Caption": "Atazanavir - Plasma concentrations",
                        "Symbol": "Circle",
                        "OutputMappings": [
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-004_400mg_TreatmentA",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-004, p. 94 - Treatment A - Atazanavir - PO - 400 mg - Plasma - agg. (n=32)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-014_400mg_YoungFemales",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-014, p. 77 - Young Females - Atazanavir - PO - 400 mg - Plasma - agg. (n=14)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-014_400mg_YoungMales",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-014, p. 77 - Young Males - Atazanavir - PO - 400 mg - Plasma - agg. (n=15)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-015_400mg_NormalSubjects",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-015, p. 81 - Normal subjects - Atazanavir - PO - 400 mg - Plasma - agg. (n=16)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-028_200mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-028, p. 128 - A-Day 6 - Atazanavir - PO - 200 mg - Plasma - agg. (n=8)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-040_200mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-040, p. 64 - 200 mg - Atazanavir - PO - 200 mg - Plasma - agg. (n=20)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Acosta2007_300mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Acosta 2007 - Period 1 - Atazanavir - PO - 300 mg - Plasma - agg. (n=10)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-056_300mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-056, p. 134 - Atazanavir without ritonavir, Day 10 - Atazanavir - PO - 300 mg - Plasma - agg. (n=30)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Zhu2010_300mg_Atazanavir",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Zhu 2010 - Atazanvir 300 mg twice daily - Atazanavir - PO - 300 mg - Plasma - agg. (n=22)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Agarwala2003_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Agarwala 2003 - Day 6 - Atazanavir - PO - 400 mg - Plasma - agg. (n=65)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Agarwala2005a_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Agarwala 2005a - ATV 400 mg AM (N=15) - Atazanavir - PO - 400 mg - Plasma - agg. (n=15)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Agarwala2005b_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Agarwala 2005b - ATV 400 mg (Treatment A) - Atazanavir - PO - 400 mg - Plasma - agg. (n=16)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-028_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-028, p. 128 - A-Day 6 - Atazanavir - PO - 200 mg - Plasma - agg. (n=8)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-040_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-040, p. 64 - 400 mg - Atazanavir - PO - 400 mg - Plasma - agg. (n=20)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-076_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-076, p. 178 - 400 mg - Atazanavir - PO - 400 mg - Plasma - agg. (n=65)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Martin2008_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Martin 2008 - Atazanavir monotherapy (n = 24) - Atazanavir - PO - 400 mg - Plasma - agg. (n=24)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Zhu2011_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Zhu 2011 - Treatment A: Atazanavir 400 mg QPM - Atazanavir - PO - 400 mg - Plasma - agg. (n=28)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-040_800mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-040, p. 64 - 800 mg - Atazanavir - PO - 800 mg - Plasma - agg. (n=20)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-076_800mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-076, p. 178 - 800 mg - Atazanavir - PO - 800 mg - Plasma - agg. (n=66)",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "Atazanavir - Dose fraction excreted unchanged in urine",
                        "Symbol": "Diamond",
                        "OutputMappings": [
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-014_400mg_YoungMales",
                                "Output": "Organism|Kidney|Urine|Atazanavir|Fraction excreted to urine",
                                "ObservedData": "ClinPharmReview, AI424-029, p. 47 - Urinary radioactivity - Atazanavir - PO - 400  - Urine - agg. (n=12)",
                                "Color": "#000000"
                            }
                        ]
                    }
                ]
            },
            {
                "Title": "Goodness-of-fit visual diagnostic plots for atazanavir PBPK model performance: weighted residuals versus time",
                "SectionId": 41,
                "PlotType": "residualsOverTime",
                "Groups": [
                    {
                        "Caption": "Atazanavir - Plasma concentrations",
                        "Symbol": "Circle",
                        "OutputMappings": [
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-004_400mg_TreatmentA",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-004, p. 94 - Treatment A - Atazanavir - PO - 400 mg - Plasma - agg. (n=32)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-014_400mg_YoungFemales",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-014, p. 77 - Young Females - Atazanavir - PO - 400 mg - Plasma - agg. (n=14)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-014_400mg_YoungMales",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-014, p. 77 - Young Males - Atazanavir - PO - 400 mg - Plasma - agg. (n=15)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-015_400mg_NormalSubjects",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-015, p. 81 - Normal subjects - Atazanavir - PO - 400 mg - Plasma - agg. (n=16)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-028_200mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-028, p. 128 - A-Day 6 - Atazanavir - PO - 200 mg - Plasma - agg. (n=8)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-040_200mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-040, p. 64 - 200 mg - Atazanavir - PO - 200 mg - Plasma - agg. (n=20)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Acosta2007_300mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Acosta 2007 - Period 1 - Atazanavir - PO - 300 mg - Plasma - agg. (n=10)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-056_300mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-056, p. 134 - Atazanavir without ritonavir, Day 10 - Atazanavir - PO - 300 mg - Plasma - agg. (n=30)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Zhu2010_300mg_Atazanavir",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Zhu 2010 - Atazanvir 300 mg twice daily - Atazanavir - PO - 300 mg - Plasma - agg. (n=22)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Agarwala2003_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Agarwala 2003 - Day 6 - Atazanavir - PO - 400 mg - Plasma - agg. (n=65)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Agarwala2005a_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Agarwala 2005a - ATV 400 mg AM (N=15) - Atazanavir - PO - 400 mg - Plasma - agg. (n=15)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Agarwala2005b_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Agarwala 2005b - ATV 400 mg (Treatment A) - Atazanavir - PO - 400 mg - Plasma - agg. (n=16)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-028_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-028, p. 128 - A-Day 6 - Atazanavir - PO - 200 mg - Plasma - agg. (n=8)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-040_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-040, p. 64 - 400 mg - Atazanavir - PO - 400 mg - Plasma - agg. (n=20)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-076_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-076, p. 178 - 400 mg - Atazanavir - PO - 400 mg - Plasma - agg. (n=65)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Martin2008_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Martin 2008 - Atazanavir monotherapy (n = 24) - Atazanavir - PO - 400 mg - Plasma - agg. (n=24)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "Zhu2011_400mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Zhu 2011 - Treatment A: Atazanavir 400 mg QPM - Atazanavir - PO - 400 mg - Plasma - agg. (n=28)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-040_800mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-040, p. 64 - 800 mg - Atazanavir - PO - 800 mg - Plasma - agg. (n=20)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-076_800mg",
                                "Output": "Organism|PeripheralVenousBlood|Atazanavir|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "ClinPharmReview, AI424-076, p. 178 - 800 mg - Atazanavir - PO - 800 mg - Plasma - agg. (n=66)",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "Atazanavir - Dose fraction excreted unchanged in urine",
                        "Symbol": "Diamond",
                        "OutputMappings": [
                            {
                                "Project": "Atazanavir",
                                "Simulation": "FDA-ClinPharmReview_AI424-014_400mg_YoungMales",
                                "Output": "Organism|Kidney|Urine|Atazanavir|Fraction excreted to urine",
                                "ObservedData": "ClinPharmReview, AI424-029, p. 47 - Urinary radioactivity - Atazanavir - PO - 400  - Urine - agg. (n=12)",
                                "Color": "#000000"
                            }
                        ]
                    }
                ]
            }
        ],
        "AllPlots": [
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-004_400mg_TreatmentA",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-014_400mg_YoungFemales",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-014_400mg_YoungMales",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-015_400mg_NormalSubjects",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-028_200mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-040_200mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "Acosta2007_300mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-056_300mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "Zhu2010_300mg_Atazanavir",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "Agarwala2003_400mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "Agarwala2005a_400mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "Agarwala2005b_400mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-028_400mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-040_400mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-076_400mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "Martin2008_400mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "Zhu2011_400mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-040_800mg",
                "SectionId": 42
            },
            {
                "Project": "Atazanavir",
                "Simulation": "FDA-ClinPharmReview_AI424-076_800mg",
                "SectionId": 42
            }
        ]
    },
    "Inputs": [
        {
            "Project": "Atazanavir",
            "Name": "Atazanavir",
            "Type": "Compound",
            "SectionId": 40
        }
    ],
    "Sections": [
        {
            "Id": 1,
            "Title": "1 Introduction",
            "Content": "Content/Section1_Introduction.md"
        },
        {
            "Id": 2,
            "Title": "2 Methods",
            "Content": "Content/Section2_Methods.md",
            "Sections": [
                {
                    "Id": 21,
                    "Content": "Content/Section2.1_Modeling_Strategy.md",
                    "Title": "2.1 Modeling strategy"
                },
                {
                    "Id": 22,
                    "Content": "Content/Section2.2_Data_used.md",
                    "Title": "2.2 Data used"
                },
                {
                   "Id": 23,
                    "Content": "Content/Section2.3_Model_Parameters_and_Assumptions.md",
                    "Title": "2.3 Model parameters and assumptions"
                }
            ]
        },
        {
            "Id": 2,
            "Content": "Content/Section3_Results_and_Discussion.md",
            "Title": "3 Results and Discussion",
            "Sections": [
                {
                    "Id": 40,
                    "Content": "Content/Atazanavir_table.md",
                    "Title": "3.1 Atazanavir final input parameters"
                },
                {
                    "Id": 41,
                    "Content": "Content/GOF_diagnostics.md",
                    "Title": "3.2 Atazanavir Diagnostics Plots"
                },
                {
                    "Id": 42,
                    "Content": "Content/Concentration_time_profiles.md",
                    "Title": "3.3 Atazanavir Concentration-Time profiles"
                }
            ]
        },
        {
            "Id": 3,
            "Content": "Content/Section4_Conclusion.md",
            "Title": "4 Conclusion"
        },
        {
            "Id": 4,
            "Content": "Content/References.md",
            "Title": "5 References"
        }
    ]
}